1-4 of 4
Larry D. Anderson, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, MD PhD, Nitya Nathwani, MD, Nina D. Shah, MD, Yvonne A. Efebera, MD MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD, Robert Z. Orlowski, MD PhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 691.
https://doi.org/10.1182/blood-2019-123465
Published: 2019
Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Meletios A. Dimopoulos, MD, Katja C. Weisel, MD, Philippe Moreau, MD, Larry D. Anderson, MD PhD, Darrell J White, MD, Jesús San-Miguel, Pieter Sonneveld, Monika Engelhardt, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Alessandro Corso, Jan Dürig, Michel Pavic, MD, Morten Salomo, MD PhD, Eva Casal, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Tuong Vi Nguyen, Tsvetan Biyukov, MD, Teresa Peluso, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3120.
https://doi.org/10.1182/blood-2019-124349
Published: 2019
Journal Articles

A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy

J Christine Ye, MDMSc, Philip S Boonstra, PhD, Daniel F. Boyer, MD PhD, Larry D. Anderson, MD PhD, Brea C. Lipe, MD, Andrew Kin, MD, Erica L. Campagnaro, MD, Matthew J. Pianko, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3191.
https://doi.org/10.1182/blood-2019-132204
Published: 2019
Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 31.
https://doi.org/10.1182/blood.V124.21.31.31
Published: 2014